New hope for advanced endometrial cancer: immunotherapy combo under study
NCT ID NCT05112991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, envafolimab (an immunotherapy) and lenvatinib (a targeted therapy), alone or together, in 108 people with advanced endometrial cancer that has worsened after standard chemotherapy. The main goal is to see if the drugs shrink tumors. Researchers will also track how long any response lasts and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- envafolimab (an immunotherapy drug) and lenvatinib (a targeted therapy drug)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced endometrial cancer who have not responded to standard chemotherapy.
- What could go wrong
- This is an early Phase II trial with only 108 participants, so results may not apply to everyone. The drugs can cause side effects like fatigue, high blood pressure, or immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
:Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, 430079, China
-
:Linyi Cancer Hospital
RECRUITINGLinyi, Shandong, 276002, China
-
:Nanjing Maternity and Child Health Care Hospital
RECRUITINGNanjing, Jiangsu, 210004, China
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Cancer Hospital of The University of Chinese Academy of Sciences
RECRUITINGHangzhou, Zhejiang, 310005, China
-
Chongqing University Three Gorges Hospital
RECRUITINGChongqing, Chongqing Municipality, 40030, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
-
Ganzhou Cancer Hospital
RECRUITINGGanzhou, Jiangxi, 341005, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450003, China
-
Liaoning Cancer Hospital
RECRUITINGShenyang, Liaoning, 110801, China
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, 250063, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
Sun Yat-Sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
-
Tai'an Center Hospital
RECRUITINGTai’an, Shandong, 271099, China
-
The Second Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, 200001, China
-
Tianjin Medical University Cancer Institute&Hospital
RECRUITINGTianjing, Tianjing, 300181, China
-
Wuhan Union Hospital of China
RECRUITINGWuhan, Hubei, 430022, China
-
Yueyang Center Hospital
RECRUITINGYueyang, Hunan, 414604, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
- New antibody drug targets Hard-to-Treat cancers in early trial
- New drug combo shows promise for tough gynecological cancers
- New combo therapy shows promise for advanced uterine cancer
- Immune cell combo shows promise against tough gynecologic cancers
- Cancer drug cocktail shows promise for uterine tumors, but trial halted early